Literature DB >> 18079364

Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis.

Yasuhiro Masubuchi1, Kanako Enoki, Toshiharu Horie.   

Abstract

Hepatic cytochrome P450 (P450) enzymes are down-regulated during inflammation. In this study, an animal model of inflammatory bowel disease was subjected to characterization of hepatic P450 expression under inflammatory conditions. Rats were treated intracolonically with 100 mg/kg trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol, and homogenates of colonic mucosa and hepatic microsomes of the rats were prepared. The colitis was accompanied by appearance of higher levels of portal endotoxin, interleukin-6, and nitric oxide metabolites and decreases in contents and activities for hepatic CYP3A2, CYP2C11, and, to a lesser extent, CYP1A2 and CYP2E1. Nimesulide, a preferential COX-2 inhibitor, protected rats with TNBS-induced colitis (TNBS-colitis) against the down-regulation of hepatic CYP3A2. Polymyxin B, which neutralizes endotoxin, curcumin, which has anti-inflammatory properties, and gadolinium chloride, which inactivates macrophages, attenuated the down-regulation of CYP3A2. Similar effects were observed in other P450s such as CYP2C11, but the agents were less effective in attenuating the down-regulation. Our data suggest that endogenous substances leaked from damaged colon in the rats with TNBS-colitis activate Kupffer cells, leading to down-regulation of hepatic P450s with differential susceptibility to the inflammatory stimuli. The colitis model, instead of exogenous administration of lipopolysaccharide or cytokines, could be applied to the study on mechanisms for altered hepatic P450 expression and other liver functions under mild inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079364     DOI: 10.1124/dmd.107.018754

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Authors:  Gezim Lahu; Andreas Hünnemeyer; Edgar Diletti; Martin Elmlinger; Peter Ruth; Karl Zech; Nigel McCracken; Axel Facius
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

Review 2.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

3.  TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease.

Authors:  Madhusudana R Chaluvadi; Beatrice A Nyagode; Ryan D Kinloch; Edward T Morgan
Journal:  Biochem Pharmacol       Date:  2008-11-06       Impact factor: 5.858

4.  Identification of novel mRNAs and lncRNAs associated with mouse experimental colitis and human inflammatory bowel disease.

Authors:  Carl Robert Rankin; Evangelos Theodorou; Ivy Ka Man Law; Lorraine Rowe; Efi Kokkotou; Joel Pekow; Jiafang Wang; Martín G Martín; Charalabos Pothoulakis; David Padua
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-28       Impact factor: 4.871

5.  Intestinal and hepatic expression of cytochrome P450s and mdr1a in rats with indomethacin-induced small intestinal ulcers.

Authors:  Shoji Kawauchi; Tsutomu Nakamura; Hiroyuki Yasui; Chikako Nishikawa; Ikuya Miki; Jun Inoue; Sayo Horibe; Tsuneo Hamaguchi; Toshihito Tanahashi; Shigeto Mizuno
Journal:  Int J Med Sci       Date:  2014-09-13       Impact factor: 3.738

6.  Cytoprotective effects of β-melanocortin in the rat gastrointestinal tract.

Authors:  Mirna Bradamante; Petra Turčić; Nikola Stambuk; Paško Konjevoda; Gorana Aralica; Ivan Alerić; Ana Kozmar
Journal:  Molecules       Date:  2012-10-01       Impact factor: 4.411

7.  Simultaneous Determination of Three Furanocoumarins by UPLC/MS/MS: Application to Pharmacokinetic Study of Angelica dahurica Radix after Oral Administration to Normal and Experimental Colitis-Induced Rats.

Authors:  Youn-Hwan Hwang; Hye Jin Yang; Jin Yeul Ma
Journal:  Molecules       Date:  2017-03-07       Impact factor: 4.411

8.  The key role of gut-liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity.

Authors:  Yisheng He; Jiang Ma; Xiaoyu Fan; Liang Ding; Xinxin Ding; Qing-Yu Zhang; Ge Lin
Journal:  Acta Pharm Sin B       Date:  2021-07-21       Impact factor: 11.413

Review 9.  The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.

Authors:  Kuo-Chen Wu; Chun-Jung Lin
Journal:  J Food Drug Anal       Date:  2018-12-04       Impact factor: 6.157

Review 10.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.